Loading...
01/10 17:30
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates strong financial performance with a 121% revenue increase and improved margins. Despite ongoing challenges like supply chain issues and potential tariff impacts, the company shows resilience with strategic plans to mitigate risks. The Q&A reveals optimism about growth and product launches, though some uncertainties remain. The absence of a shareholder return plan is a minor drawback. Overall, the positive revenue growth, strategic partnerships, and improved financial health suggest a positive stock price movement in the short term.
Revenue $2.81 million, an increase of 121% year-over-year compared to $1.27 million for Q1 2024, primarily due to sales growth in both contract manufacturing and branded products.
Cost of Revenues $1.62 million, compared to $1.1 million for Q1 2024, aligned with the increase in revenue growth.
Gross Profit $1.19 million, compared to $0.16 million for Q1 2024, with a gross profit margin of 42.4% compared to 12.6% for Q1 2024, primarily due to the increase in overall sales.
Selling, General and Administrative Expenses $1.96 million, compared to $1.03 million for Q1 2024, attributable to increases in compensation and benefits, share-based compensation, advertising, marketing, Amazon fees, professional and consulting fees, and other fees.
EBITDA Negative $0.54 million, compared to negative $0.84 million for Q1 2024, reflecting improved operational performance.
Adjusted EBITDA Negative $0.47 million, compared to negative $0.73 million for Q1 2024, indicating a narrowing loss.
Net Loss $0.71 million, compared to a net loss of $0.85 million for Q1 2024, showing an improvement in net loss.
Cash Balance Approximately $1.19 million as of March 31, 2025.
New Product Launches: Medagel will expand its product line with the anticipated launch of several new offerings, including the SilverSeal wound and burn kit and its moist burn pads. Kenkoderm will double the size of its product portfolio in the third quarter of 2025 with the launch of new products for eczema. Silly George will launch complementary beauty products, including five shades of lip gloss, a hydrating lip mask, and undereye patches featuring proprietary hydrogel technology.
Market Expansion: Received approval from Health Canada to sell SilverSeal in that territory. Partnership with STADA is expanding beyond Histasolv, with plans to launch another product in Q4 2025.
Operational Efficiency: Gross margins normalized to 42.4%, aligning with historical ranges. Contract manufacturing revenue increased 58% year-over-year. Consumer branded products increased 189% year-over-year, led by Silly George.
Strategic Shift: Exploring the possibility to use a new clean room in Texas for assembly to mitigate tariff impacts. Focus on driving innovation and growth across key business segments to deliver long-term value.
Regulatory Issues: The launch of AbbVie's RESONIC machine has been delayed due to manufacturing issues unrelated to NEXGEL, which may impact revenue opportunities.
Supply Chain Challenges: Potential tariff increases on products sourced from China could affect costs, particularly if tariffs rise from 34% to 145%. NEXGEL is monitoring this situation closely and may need to adjust its supply chain strategy.
Competitive Pressures: Increased interest in U.S.-made gels may provide a competitive advantage, but the company must remain vigilant about cheaper alternatives from abroad.
Economic Factors: The overall economic environment and potential fluctuations in consumer demand could impact revenue projections and growth.
Contract Manufacturing Growth: Contract manufacturing revenue increased 58% year-over-year, driven by demand from existing customers and onboarding of new global corporations.
Consumer Branded Products Growth: Consumer branded products revenue increased 189% year-over-year, led by the addition of Silly George.
New Product Launches: Medagel will launch new offerings including SilverSeal wound and burn kit and moist burn pads. Kenkoderm will double its product portfolio in Q3 2025.
Partnerships: Partnership with STADA is expanding, with plans to launch another product in Q4 2025 and several more in 2026.
FDA Study: A 30-patient human trial for hydrogel efficacy in laser hair removal is complete, awaiting publication.
Revenue Guidance: The company maintains its revenue guidance of $13 million for 2025.
Cash Flow Positivity: NEXGEL expects to achieve cash flow positivity in 2025.
Gross Margin Outlook: Gross margins normalized to 42.4%, aligning with historical ranges.
Future Opportunities: The company has a robust pipeline of new customers and applications for hydrogels, indicating potential for continued growth.
Shareholder Return Plan: NEXGEL has not announced any share buyback program or dividend program during the call.
The earnings call presents a mixed outlook. Financial performance is stable with improved margins and narrowed losses, but logistical delays and dependence on key partnerships pose risks. The Q&A reveals uncertainties, particularly with AbbVie and logistical challenges, dampening optimism. The reaffirmed guidance and potential positive EBITDA are countered by economic uncertainties and cash flow challenges. Without a clear market cap, the sentiment remains neutral, balancing positive operational efficiencies against logistical and partnership risks.
The earnings call summary and Q&A section reveal strong financial performance, with 121% revenue growth and positive developments in consumer products. Strategic partnerships with major companies like AbbVie suggest future revenue potential despite delays. The company maintains guidance and expects cash flow positivity, indicating financial health. Although there are some uncertainties, like the AbbVie timeline and tariff impacts, the overall sentiment is positive, especially with strong sales from Silly George and new product launches. The positive sentiment outweighs the negatives, suggesting a likely positive stock price movement.
The earnings call indicates strong financial performance with a 121% revenue increase and improved margins. Despite ongoing challenges like supply chain issues and potential tariff impacts, the company shows resilience with strategic plans to mitigate risks. The Q&A reveals optimism about growth and product launches, though some uncertainties remain. The absence of a shareholder return plan is a minor drawback. Overall, the positive revenue growth, strategic partnerships, and improved financial health suggest a positive stock price movement in the short term.
The earnings call highlights a significant revenue increase, strong gross profit margins, and optimistic future guidance, which are positive indicators. While there are concerns about tariffs and regulatory issues, these are being actively managed. The lack of a shareholder return plan is a minor negative, but the partnership with STADA and the consistent growth in Silly George's margins are strong positives. Overall, the positive financial performance and strategic partnerships outweigh the risks, suggesting a positive stock price movement over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
